Author

Katrin Kleinmanns

Haukeland University HospitalORCID 0000-0003-1402-8568Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Emmet McCormackiD· 2 shared Line BjørgeiD· 2 shared Anna PirttikoskiiD· 1 shared Anna VähärautioiD· 1 shared Benno SchwikowskiiD· 1 shared Carola DoerriD· 1 shared Cecilie Fredvik TorkildseniD· 1 shared Daniela Elena CosteaiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Emmet McCormackORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 6, 2026

Single-Cell Transcriptomic Signatures Enable Stratified Combination Therapy for Platinum-Resistant Ovarian Cancer

Laura Gall-Mas, Katrin Kleinmanns, Anna Pirttikoski…·Benno Schwikowski

The paper uses single-cell RNA sequencing to identify resistance signatures in ovarian cancer and develops a framework for combination therapy with carboplatin.

DOI 10.64898/2026.03.04.709546

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyInternational Journal of Gynecological CancerPeer-reviewedFeb 1, 2026

Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Luka Tandarić, Line Bjørge, Martine Rott Lode…·Katrin Kleinmanns

This study develops a humanized xenograft model of high-grade serous ovarian cancer to evaluate immunotherapy, finding no treatment response but identifying immune-excluded tumor phenotypes.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky